Important safety information -- Revised directions for using Rabies Immune Globulin (Human), HyperRAB ™ S/D in fixed needle 2 mL prefilled syringe
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Important safety information -- Revised directions for using Rabies Immune Globulin (Human), HyperRAB ™ S/D in fixed needle 2 mL prefilled syringe

Filetype[PDF-22.47 KB]


  • English
    • Details You May Also Like

    Details:

    • Alternative Title:
      Revised directions for using Rabies Immune Globulin (Human), HyperRAB ™ S/D in fixed needle 2 mL prefilled syringe
    • Journal Article:
      HAN
    • Corporate Authors:
      Centers for Disease Control and Prevention (U.S.)
    • Description:
      Tuesday, February 26, 2008, 20:15 EST (8:15 PM EST)

      CDCHAN-00270-2008-02-26-ADV-N

      The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have been notified by Talecris Biotherapeutics, Inc. that its Rabies Immune Globulin (Human), HyperRAB™ S/D in fixed needle 2 mL pre-filled syringe does not address all dosing situations. Specifically, the fixed needle (22 gauge, 1.25 inch) and the absence of graduations on the 2 mL pre-filled syringe do not permit administration of the recommended dose of Rabies Immune Globulin (Human), HyperRAB™ S/D in one or more of the following situations:

      • A dose < 2 mL is required (e.g. for pediatric use);

      • A dose < 2 mL must be injected over multiple sites; or

      • An alternate needle (different length or gauge) is required based on the patient (adult or child), wound or site of injection.

      Healthcare providers may continue to administer HyperRAB S/D supplied in the 2 mL pre-filled syringe by following the "Revised Directions for Use" that are packaged with these lots. The full "Revised Directions for Use" of these lots is available on-line: http://www.talecris.com/us/documents/FINAL_FDA_Approved_Revised_ Directions_for_Syringe_Use 21-FEB-08.pdf . Talecris has discontinued manufacturing the HyperRAB™S/D fixed needle, 2 mL pre-filled syringe.

    • Subjects:
    • Series:
      HAN ; 270
    • Document Type:
      HAN Health Advisory
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov